SCHEMBL13342902

SCHEMBL13342902

CCN(CC)C(=O)Oc1ccc(Cl)cc1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.55
▸ TSHR P16473 3/20 0.55
▸ SMN1; SMN2 Q16637 4/20 0.52
▸ KDM4E B2RXH2 4/20 0.51
▸ L3MBTL1 Q9Y468 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ CYP1A2 P05177 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ HIF1A Q16665 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48
▸ HPGD P15428 2/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ HTR2A P28223 1/20 0.48
▸ HTR2C P28335 1/20 0.48
▸ HTR2B P41595 1/20 0.48
▸ MAPT P10636 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16965114 0.87 LMNA (0.57) LMNATSHRSMN1; SMN2KDM4EL3MBTL1
SCHEMBL29728538 0.87 LMNA (0.57) LMNATSHRSMN1; SMN2KDM4EL3MBTL1
SCHEMBL13342926 0.85 NPSR1 (0.50) LMNATSHRSMN1; SMN2KDM4EL3MBTL1
SCHEMBL13342923 0.84 CYP1A2 (0.47) TSHRSMN1; SMN2KDM4EMEN1KMT2A
SCHEMBL13368630 0.84 MEN1 (0.53) LMNATSHRSMN1; SMN2KDM4EL3MBTL1
SCHEMBL22372573 0.83 LMNA (0.54) LMNATSHRSMN1; SMN2KDM4EL3MBTL1
SCHEMBL11773011 0.82 KDM4E (0.45) LMNATSHRSMN1; SMN2KDM4EMEN1
SCHEMBL13342911 0.82 LMNA (0.55) LMNATSHRSMN1; SMN2KDM4EMEN1
SCHEMBL11771110 0.81 TSHR (0.50) LMNATSHRSMN1; SMN2KDM4EMEN1
SCHEMBL9799902 0.79 CYP1A2 (0.56) LMNATSHRSMN1; SMN2KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-05-06 — — US disclosed
US-7626042-B2 O-substituted hydroxyaryl derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-01 — — US disclosed
US-7626042-B2 O-substituted hydroxyaryl derivatives INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-12-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113770-A1 O-SUBSTITUTED HYDROXYARYL DERIVATIVES RELA, NFKBIA, NFE2 LMNA 349/4885TSHR 3471/4885SMN1; SMN2 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback